 SOLIUS, a developer of innovative light therapy technologies focused on mitigating vitamin D deficiency, today announced investment from Human Longevity, Inc. (HLI) into its Series B financing.

Human Longevity, Inc. (HLI) is a genomics-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI's business focus includes the Health Nucleus, a genomic-powered, precision medicine center which uses whole-genome sequencing analysis, advanced imaging, and blood analytics, to deliver the most complete picture of individual health.

SOLIUS Announces Investment from Human Longevity Inc. to Support Mission of Improving Health, Performance, and Longevity.

SOLIUS Announces Investment from Human Longevity Inc. to Support Mission of Improving Health, Performance, and Longevity.

Company Info